Hearing in renal failure

Thodi, Chryssoula; Thodis, Elias; Danielides, Vassilis; Pasadakis, Ploumis; Vargemezis, Vassilis

doi:10.1093/ndt/gfl472

Cited by 75 publications

(74 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The glomerulus is not functioning actively; therefore, physiological changes are likely to occur in the body, including changes to the cochlea. These changes are specific to the stria vascularis as a result of the electrolyte imbalance (Thodi et al, 2006). This was confirmed by electrolyte, urea and creatinine levels particularly for stage 5 patients extending outside of the normative ranges.…”

Section: Discussionmentioning

confidence: 54%

Cochlear function in patients with chronic kidney disease

Govender

Matthews

2013

South African Journal of Communication Disorders

View full text Add to dashboard Cite

Objective: To evaluate cochlear functioning in patients (18 - 45 years old) with varying stages of chronic kidney disease (CKD). Using purposive sampling, 50 participants, 10 in each of the 5 stages of CKD, were selected and underwent pure tone audiometric testing and distortion product otoacoustic emissions (DPOAEs).Results: Significant differences (p<0.05) were found between pure tone audiometry and DPOAEs in detecting early cochlear dysfunction in the high-frequency range in stages 3 (6 000/5 000 Hz; p=0.00), 4 (6 000/5 000 Hz; p<0.03) and 5 (4 000/3 333 Hz; p<0.01, 8 000/6 667 Hz:p<0.05) with DPOAEs being more sensitive in identifying early cochlear dysfunction. Patients in stages 1 and 2 presented with normal puretone thresholds and DPOAEs, suggesting that cochlear functioning in these patients was normal. Early cochlear dysfunction, thereby indicating a subclinical hearing loss, was identified in stages 3, 4 and 5 by DPOAE testing. In addition, blood test results, drug intake and concomitant conditions were recorded and analysed which suggested a relationship between reduced cochlear functioning and increased electrolyte levels, treatment regimens and concomitant conditions.Conclusion: Participants in the later stages of CKD presented with early cochlear dysfunction, presenting with subclinical hearing loss. It was postulated that this subclinical hearing loss resulted from a combination of electrolytic, urea and creatinine imbalances, together with concomitant medical conditions and ototoxic drug intake. It was concluded that audiological monitoring be included in the management of patients with CKD and that DPOAEs be introduced as part of the test battery to monitor cochlear function in patients with varying degrees of CKD.

show abstract

Section: Discussionmentioning

confidence: 54%

Cochlear function in patients with chronic kidney disease

Govender

Matthews

2013

South African Journal of Communication Disorders

View full text Add to dashboard Cite

show abstract

“…Hearing loss is a nonspecific feature of several hereditary nephropathies. Sensorineural hearing loss is also frequently reported in patients with chronic renal failure, although the exact etiology of this hearing impairment remains unclear (6). Renal biopsies should be examined by light and electron microscopy.…”

Section: Introductionmentioning

confidence: 99%

The Value of Clinical Criteria in Identifying Patients with X-Linked Alport Syndrome

Hanson¹,

Storey²,

Pagan³

et al. 2011

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryBackground and objectives Alport syndrome (AS) is a predominantly X-linked hereditary nephritis associated with high-tone, sensorineural deafness and characteristic eye signs. Clinical diagnostic criteria were defined in 1988. Most cases result from mutations in the X-linked collagen gene COL4A5, with mutations in the autosomal genes COL4A3 and COL4A4 on chromosome 2 accounting for the rest. Mutation analysis of COL4A5 with a combination of sequencing and multiplex ligation-dependent probe amplification has been available for several years. The objective of this study was to determine the utility of clinical diagnostic criteria in identifying patients likely to have a COL4A5 mutation.Design, setting, participants, & measurements Clinical information was available on 206 patients whose DNA was received for testing between 1994 and June 2008; predictive tests for a known familial mutation, samples from duplicate family members, and incompletely screened samples were excluded. One hundred and twenty-eight patients (62.1%) had a pathogenic COL4A5 mutation.Results The mutation detection rate in families fulfilling zero, one, two, three, or four diagnostic criteria was 0%, 18%, 64%, 89%, and 81%, respectively. Sixty-seven percent of patients with COL4A5 mutations meeting only two diagnostic criteria had not had a complete clinical assessment. In two thirds of families meeting four diagnostic criteria without an identified COL4A5 mutation, autosomal inheritance was confirmed or suspected. ConclusionsThe authors recommend COL4A5 analysis in any patient meeting at least two clinical diagnostic criteria. COL4A3 and COL4A4 analysis should be considered if a COL4A5 mutation is not detected and primarily if autosomal inheritance is suspected.

show abstract

“…Antonelli et al [1] presented a detailed review of possible causes of hearing loss in patients with end stage CRF; they stipulated that even with strict control for confounding variables, there remains evidence of sensorineural hearing loss. Thodi et al [2] reviewed published research exploring hearing in end stage CRF and concluded that auditory function is affected by end stage CRF in various degrees in all reported studies, with findings of damage across the auditory pathway.…”

Section: Introductionmentioning

confidence: 99%

Auditory Brainstem Responses in Patients under Treatment of Hemodialysis

Aspris

Thodi²,

Balatsouras

et al. 2008

Renal Failure

View full text Add to dashboard Cite

This study evaluated the effects of end stage chronic renal failure (CRF) on auditory function and changes in auditory function following a single session of hemodialysis. The experimental group included 31 patients with end-stage renal failure on chronic hemodialysis. The control group consisted of 31 healthy volunteers. The patients were examined prior to and following a session of hemodialysis. Measurements included pure tone audiometry, tympanometry and acoustic reflex measurements, auditory brainstem responses (ABR), and blood now chemistry parameters. Controls underwent the same test battery, with the exception of biochemical and hematological assessment. Prior to hemodialysis sessions, all ABR latencies except interpeak latency I-III were significantly prolonged in the experimental group. A comparison between controls and the experimental group following hemodialysis indicated that wave V absolute latency and interpeak latencies III-V and I-V were significantly prolonged in the slow repetition rate paradigm. In the fast repetition rate, absolute latencies of waves I and V and III-V interpeak latencies were prolonged in the experimental group. Comparison of ABR recordings prior to and following hemodialysis showed overall significant difference between the measures. Post hoc analysis showed a significant improvement in wave I and V latencies in the slow repetition rate and wave V latency in the fast repetition rate. This study showed that neural conduction along the auditory pathway is delayed in patients with end stage CRF as compared to healthy subjects. Dialysis sessions improve overall neural auditory function. However, patients with end stage CRF show delayed conduction even after a session of hemodialysis.

show abstract

Hearing in renal failure

Cited by 75 publications

References 42 publications

Cochlear function in patients with chronic kidney disease

Cochlear function in patients with chronic kidney disease

The Value of Clinical Criteria in Identifying Patients with X-Linked Alport Syndrome

Auditory Brainstem Responses in Patients under Treatment of Hemodialysis

Contact Info

Product

Resources

About